- Home
- RBB vs IMMP Comparison
RBB vs IMMP Comparison
Compare RBB & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBB
- IMMP
- Stock Information
- Founded
- RBB 2008
- IMMP 1987
- Country
- RBB United States
- IMMP Australia
- Employees
- RBB N/A
- IMMP N/A
- Industry
- RBB Major Banks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- RBB Finance
- IMMP Health Care
- Exchange
- RBB Nasdaq
- IMMP Nasdaq
- Market Cap
- RBB 280.6M
- IMMP 211.1M
- IPO Year
- RBB 2017
- IMMP N/A
- Fundamental
- Price
- RBB $16.19
- IMMP $1.86
- Analyst Decision
- RBB Hold
- IMMP Buy
- Analyst Count
- RBB 4
- IMMP 2
- Target Price
- RBB $21.25
- IMMP $8.50
- AVG Volume (30 Days)
- RBB 31.1K
- IMMP 648.0K
- Earning Date
- RBB 04-28-2025
- IMMP 05-16-2025
- Dividend Yield
- RBB 3.92%
- IMMP N/A
- EPS Growth
- RBB N/A
- IMMP N/A
- EPS
- RBB 1.17
- IMMP N/A
- Revenue
- RBB $98,305,000.00
- IMMP $3,019,249.00
- Revenue This Year
- RBB $14.95
- IMMP $11.25
- Revenue Next Year
- RBB $7.77
- IMMP $10.22
- P/E Ratio
- RBB $13.96
- IMMP N/A
- Revenue Growth
- RBB N/A
- IMMP 24.11
- 52 Week Low
- RBB $14.40
- IMMP $1.32
- 52 Week High
- RBB $25.30
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- RBB 50.84
- IMMP 53.43
- Support Level
- RBB $14.66
- IMMP $1.44
- Resistance Level
- RBB $16.04
- IMMP $2.71
- Average True Range (ATR)
- RBB 0.67
- IMMP 0.17
- MACD
- RBB 0.10
- IMMP 0.05
- Stochastic Oscillator
- RBB 72.04
- IMMP 29.75
About RBB RBB Bancorp
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.